Amgen slides after Novartis pelacarsen failure report
Amgen shares were down more than 9% and were on pace for its largest daily decrease since October 2000. The move followed Novartis’ announcement that pelacarsen failed to reduce cardiovascular event risk.
The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a…